These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
72 related articles for article (PubMed ID: 11776055)
1. Bacterially produced human B7-1 protein encompassing its complete extracellular domain maintains its costimulatory activity in vitro. Shen W; Wang Y; Geng Y; Si L Chin Med J (Engl); 2000 Aug; 113(8):714-9. PubMed ID: 11776055 [TBL] [Abstract][Full Text] [Related]
2. Recombinant human B7.2 IgV-like domain expressed in bacteria maintains its co-stimulatory activity in vitro. Yan X; Ma J; Zheng J; Lai B; Geng Y; Wang Y; Si L Chin Med J (Engl); 2002 Jul; 115(7):1053-7. PubMed ID: 12150742 [TBL] [Abstract][Full Text] [Related]
3. Recombinant human B7-H4 expressed in Escherichia coli inhibits T lymphocyte proliferation and IL-2 secretion in vitro. Mao YX; Chen YJ; Ge Y; Ma HB; Yu JF; Wu HY; Hu YM; Wang Q; Shi Q; Zhang XG Acta Pharmacol Sin; 2006 Jun; 27(6):741-6. PubMed ID: 16723094 [TBL] [Abstract][Full Text] [Related]
4. Expression of fusion IL2-B7.1(IgV+C) and effects on T lymphocytes. Kong L; Li Y; Yang Y; Li K Biochem Cell Biol; 2007 Dec; 85(6):685-95. PubMed ID: 18059527 [TBL] [Abstract][Full Text] [Related]
5. A novel bispecific tetravalent antibody fusion protein to target costimulatory activity for T-cell activation to tumor cells overexpressing ErbB2/HER2. Biburger M; Weth R; Wels WS J Mol Biol; 2005 Mar; 346(5):1299-311. PubMed ID: 15713482 [TBL] [Abstract][Full Text] [Related]
6. Human recombinant B7-H3 expressed in E. coli enhances T lymphocyte proliferation and IL-10 secretion in vitro. Zhang GB; Chen YJ; Shi Q; Ma HB; Ge Y; Wang Q; Jiang Z; Xu Y; Zhang XG Acta Biochim Biophys Sin (Shanghai); 2004 Jun; 36(6):430-6. PubMed ID: 15188059 [TBL] [Abstract][Full Text] [Related]
7. Isoforms of human B7-H3 co-signalling molecule for T cell activation as potential immunoregulatory agents. Expert Opin Ther Pat; 2005 Jun; 15(6):745-9. PubMed ID: 20141505 [TBL] [Abstract][Full Text] [Related]
8. Non-glycosylated human B7-1(CD80) retains the capacity to bind its counter-receptors. Chen A; Meyerson HJ; Salvekar A; Tykocinski ML FEBS Lett; 1998 May; 428(3):127-34. PubMed ID: 9654121 [TBL] [Abstract][Full Text] [Related]
9. A negative regulatory role in mouse cardiac transplantation for a splice variant of CD80. Bugeon L; Wong KK; Rankin AM; Hargreaves RE; Dallman MJ Transplantation; 2006 Nov; 82(10):1334-41. PubMed ID: 17130783 [TBL] [Abstract][Full Text] [Related]
10. Suppression of human T-cell responses to beta-cells by activation of B7-H4 pathway. Ou D; Wang X; Metzger DL; Ao Z; Pozzilli P; James RF; Chen L; Warnock GL Cell Transplant; 2006; 15(5):399-410. PubMed ID: 16970282 [TBL] [Abstract][Full Text] [Related]
11. Both extracellular immunoglobin-like domains of CD80 contain residues critical for binding T cell surface receptors CTLA-4 and CD28. Peach RJ; Bajorath J; Naemura J; Leytze G; Greene J; Aruffo A; Linsley PS J Biol Chem; 1995 Sep; 270(36):21181-7. PubMed ID: 7545666 [TBL] [Abstract][Full Text] [Related]
12. A mutant B7-1/Ig fusion protein that selectively binds to CTLA-4 ameliorates anti-tumor DNA vaccination and counters regulatory T cell activity. Chakrabarti R; Zhou ZF; Chang Y; Prud'homme GJ Vaccine; 2005 Aug; 23(37):4553-64. PubMed ID: 15919138 [TBL] [Abstract][Full Text] [Related]
13. B7-1-HSA (CD80-CD24), a recombinant hybrid costimulatory molecule retains ligand binding and costimulatory functions. Wang YC; Sashidharamurthy R; Nagarajan S; Selvaraj P Immunol Lett; 2006 Jun; 105(2):185-92. PubMed ID: 16621031 [TBL] [Abstract][Full Text] [Related]
14. CD80 and CD86 IgC domains are important for quaternary structure, receptor binding and co-signaling function. Girard T; Gaucher D; El-Far M; Breton G; Sékaly RP Immunol Lett; 2014 Sep; 161(1):65-75. PubMed ID: 24845157 [TBL] [Abstract][Full Text] [Related]
16. Combination B7-Fc fusion protein treatment and Treg cell depletion therapy. Liu A; Hu P; Khawli LA; Epstein AL Clin Cancer Res; 2005 Dec; 11(23):8492-502. PubMed ID: 16322313 [TBL] [Abstract][Full Text] [Related]
17. Stable expression of chimeric anti-CD3 receptors on mammalian cells for stimulation of antitumor immunity. Liao KW; Chen BM; Liu TB; Tzou SC; Lin YM; Lin KF; Su CI; Roffler SR Cancer Gene Ther; 2003 Oct; 10(10):779-90. PubMed ID: 14502231 [TBL] [Abstract][Full Text] [Related]
18. The capacity of the natural ligands for CD28 to drive IL-4 expression in naïve and antigen-primed CD4+ and CD8+ T cells. Bian Y; Hiraoka S; Tomura M; Zhou XY; Yashiro-Ohtani Y; Mori Y; Shimizu J; Ono S; Dunussi-Joannopoulos K; Wolf S; Fujiwara H Int Immunol; 2005 Jan; 17(1):73-83. PubMed ID: 15569772 [TBL] [Abstract][Full Text] [Related]
19. Human Soluble CD80 is generated by alternative splicing, and recombinant soluble CD80 binds to CD28 and CD152 influencing T-cell activation. Kakoulidou M; Giscombe R; Zhao X; Lefvert AK; Wang X Scand J Immunol; 2007 Nov; 66(5):529-37. PubMed ID: 17953528 [TBL] [Abstract][Full Text] [Related]
20. Time courses of B7 family molecules expressed on activated T-cells and their biological significance. Sun ZW; Qiu YH; Shi YJ; Tao R; Chen J; Ge Y; Hu YM; Ma HB; Shi Q; Zhang XG Cell Immunol; 2005; 236(1-2):146-53. PubMed ID: 16165113 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]